Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
- PMID: 35542991
- DOI: 10.14283/jpad.2022.30
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
Abstract
Background: Alzheimer's disease is a progressive, irreversible, and fatal disease for which accumulation of amyloid beta is thought to play a key role in pathogenesis. Aducanumab is a human monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.
Objectives: We evaluated the efficacy and safety of aducanumab in early Alzheimer's disease.
Design: EMERGE and ENGAGE were two randomized, double-blind, placebo-controlled, global, phase 3 studies of aducanumab in patients with early Alzheimer's disease.
Setting: These studies involved 348 sites in 20 countries.
Participants: Participants included 1638 (EMERGE) and 1647 (ENGAGE) patients (aged 50-85 years, confirmed amyloid pathology) who met clinical criteria for mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia, of which 1812 (55.2%) completed the study.
Intervention: Participants were randomly assigned 1:1:1 to receive aducanumab low dose (3 or 6 mg/kg target dose), high dose (10 mg/kg target dose), or placebo via IV infusion once every 4 weeks over 76 weeks.
Measurements: The primary outcome measure was change from baseline to week 78 on the Clinical Dementia Rating Sum of Boxes (CDR-SB), an integrated scale that assesses both function and cognition. Other measures included safety assessments; secondary and tertiary clinical outcomes that assessed cognition, function, and behavior; and biomarker endpoints.
Results: EMERGE and ENGAGE were halted based on futility analysis of data pooled from the first approximately 50% of enrolled patients; subsequent efficacy analyses included data from a larger data set collected up to futility declaration and followed prespecified statistical analyses. The primary endpoint was met in EMERGE (difference of -0.39 for high-dose aducanumab vs placebo [95% CI, -0.69 to -0.09; P=.012; 22% decrease]) but not in ENGAGE (difference of 0.03, [95% CI, -0.26 to 0.33; P=.833; 2% increase]). Results of biomarker substudies confirmed target engagement and dose-dependent reduction in markers of Alzheimer's disease pathophysiology. The most common adverse event was amyloid-related imaging abnormalities-edema.
Conclusions: Data from EMERGE demonstrated a statistically significant change across all four primary and secondary clinical endpoints. ENGAGE did not meet its primary or secondary endpoints. A dose- and time-dependent reduction in pathophysiological markers of Alzheimer's disease was observed in both trials.
Keywords: Aducanumab; Alzheimer’s disease; amyloid beta.
Conflict of interest statement
These studies were funded by Biogen. SBH, YT, KKM, TC, SW, GD, KH, IN, and YZ are employees and shareholders of Biogen. SC (Dr Chalkias), AS, LN, RR, CvH, CM and LS were employees of Biogen at the time of this work. CM is a current employee of Cortexyme. LS and CvH are current employees of Takeda Pharmaceutical Co. SC is a current employee at Moderna. RR is a current employee at Vigil Neuro. PSA was chair of the Steering Committee and has consulted for Biogen, has received research support from Eli Lilly, Janssen, Eisai, the Alzheimer’s Association, the National Institutes of Health, and the Foundation for the National Institutes of Health; he has consulted for Merck, Roche and ImmunoBrain Checkpoint. PSA is co-editor in chief of JPAD with no personal compensation; he did not have a role in the editorial process/review for this manuscript. FB was supported by NIHR Biomedical Research Centre at UCLH. He receives personal fees for consultancy from Bayer, Biogen, Roche, IXICO Ltd, Novartis, and Combinostics. SC (Dr Cohen) was an ENGAGE trial site investigator and an Aducanumab Steering Committee member. She is a consultant (no personal fees received) to Biogen, Cassava Sciences, Cogstate, INmune Bio, ProMIS Neuroscience, and RetiSpec and receives research support (paid to institution) from AgeneBio, Anavex, Biogen, Cassava, Eisai, Genentech, Green Valley, Eli Lilly, Janssen, RetiSpec, Roche, and Vielight. OH received research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, Biogen, Cerveau, and Roche. TI is a consultant to Eisai and Roche. CJM was an ENGAGE trial site investigator and an Aducanumab Steering Committee member. She is supported by NIHR Biomedical Research Centre at UCLH and has acted as a consultant to Biogen, Roche, and IONIS. CvD was an EMERGE trial site investigator. He is a consultant for Roche, Eisai, and Ono and receives research support from Biogen, Eisai, Roche, Genentech, Eli Lilly, Janssen, Merck, Novartis, and Biohaven. BV is an investigator in clinical trials sponsored by Biogen, Lilly, Roche, Eisai Pharmaceuticals, and the Toulouse University Hospital (Inspire Geroscience Program). He has served as SAB member for Biogen, Alzheon, Green Valey, Norvo Nordisk, Longeveron, but received no personal compensation. He has served as consultant and/or SAB member for Roche, Lilly, Eisai, TauX with personal compensation. His family members have equity ownership interest in Serdi. He is member of the Editorial Board of JPAD with no personal compensation. He did not have a role in the editorial or peer review for this manuscript at JPAD.
Comment in
-
Ventricular enlargement caused by aducanumab.Nat Rev Neurol. 2022 Jul;18(7):383-384. doi: 10.1038/s41582-022-00660-7. Nat Rev Neurol. 2022. PMID: 35440813 No abstract available.
-
Editorial: The 'Aducanumab Story': Will the Last Chapter Spell the End of the 'Amyloid Hypothesis' or Mark a New Beginning?J Prev Alzheimers Dis. 2022;9(2):190-192. doi: 10.14283/jpad.2022.36. J Prev Alzheimers Dis. 2022. PMID: 35542989 No abstract available.
-
Editorial: Aducanumab Trials EMERGE But Don't ENGAGE.J Prev Alzheimers Dis. 2022;9(2):193-196. doi: 10.14283/jpad.2022.37. J Prev Alzheimers Dis. 2022. PMID: 35542990 No abstract available.
Similar articles
-
Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab.J Prev Alzheimers Dis. 2023;10(2):171-177. doi: 10.14283/jpad.2023.6. J Prev Alzheimers Dis. 2023. PMID: 36946443 Clinical Trial.
-
Aducanumab for the treatment of Alzheimer's disease: a systematic review.Psychogeriatrics. 2023 May;23(3):512-522. doi: 10.1111/psyg.12944. Epub 2023 Feb 12. Psychogeriatrics. 2023. PMID: 36775284 Review.
-
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.JAMA Neurol. 2022 Jan 1;79(1):13-21. doi: 10.1001/jamaneurol.2021.4161. JAMA Neurol. 2022. PMID: 34807243 Free PMC article. Clinical Trial.
-
Aducanumab: First Approval.Drugs. 2021 Aug;81(12):1437-1443. doi: 10.1007/s40265-021-01569-z. Drugs. 2021. PMID: 34324167 Review.
-
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).Alzheimers Res Ther. 2018 Sep 19;10(1):96. doi: 10.1186/s13195-018-0424-5. Alzheimers Res Ther. 2018. PMID: 30231896 Free PMC article. Clinical Trial.
Cited by
-
The path to next-generation disease-modifying immunomodulatory combination therapies in Alzheimer's disease.Nat Aging. 2024 Jun;4(6):761-770. doi: 10.1038/s43587-024-00630-2. Epub 2024 Jun 5. Nat Aging. 2024. PMID: 38839924 Review.
-
Box-Behnken Design-Based Optimization of Phytochemical Extraction from Diplazium esculentum (Retz.) Sw. Associated with Its Antioxidant and Anti-Alzheimer's Properties.Molecules. 2024 May 8;29(10):2204. doi: 10.3390/molecules29102204. Molecules. 2024. PMID: 38792065 Free PMC article.
-
Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer's Disease.Int J Mol Sci. 2024 May 9;25(10):5169. doi: 10.3390/ijms25105169. Int J Mol Sci. 2024. PMID: 38791206 Free PMC article. Review.
-
Passive Anti-Amyloid Beta Immunotherapies in Alzheimer's Disease: From Mechanisms to Therapeutic Impact.Biomedicines. 2024 May 15;12(5):1096. doi: 10.3390/biomedicines12051096. Biomedicines. 2024. PMID: 38791059 Free PMC article. Review.
-
Diffusion imaging markers of accelerated aging of the lower cingulum in subjective cognitive decline.Front Neurol. 2024 May 9;15:1360273. doi: 10.3389/fneur.2024.1360273. eCollection 2024. Front Neurol. 2024. PMID: 38784911 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous